Biosynex, the results you need when it matters most

Pharmacist and Chemist

  • Pharmacy
  • Parapharmacy
Home header hover
Landing page pharma biosynex

Our products

Physician and Biologist

  • Laboratory
  • Primary Care
Home header hover
Accueil Biologiste Biosynex

Our products
Physician and Biologist


Who are we ?

Specialising in the design and distribution of rapid diagnostic tests in France and in more than 90 countries, Biosynex, French laboratory, created in 2005, offers healthcare solutions that improve the overall treatment of patients.

In close collaboration with healthcare professionals (pharmacists, laboratory technicians, doctors, hospitals, etc.), we develop rapid, simple and practical solutions that facilitate the prevention, screening and implementation of medical treatments adapted to the needs of both patient and healthcare professional.

With annual sales of €383 million in 2021, it is the French market leader in rapid tests

Learn more

About us

The news

  • logo procisedx biosynex
    12 June 2023


    We are pleased to announce the acquisition of the North American company ProciseDx! This acquisition strengthens our laboratory's presence in the United States, and represents a...

  • chembio logo biosynex
    2 May 2023

    SEC CHEMBIO documents

    Documents filed with the SEC. Acquisition of CHEMBIO DIAGNOSTICS:

  • chembio logo biosynex
    15 March 2023

    Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement

    Find out more about BIOSYNEX and CHEMBIO: • Project Merci – Schedule to tender offert statement under section 14(d)(1) or 13(e)(1) of the securities exchange...

  • 17 January 2023

    Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A.

    « BIOSYNEX and Credo Diagnostics have recently strengthened their collaboration by signing an exclusivity agreement for an extended territory including the United Kingdom. Thanks to...

  • 4 January 2023

    Biosynex announces the acquisition of a 75% stake in Danish company Medkoncept AS

    As part of its international development, BIOSYNEX announces that it has acquired a 75% majority stake,alongside the two founders, in MEDKONCEPT AS, a company based...

  • 20 April 2022

    Biosynex has acquired Parakito

    « Biosynex has acquired PARAKITO, operated by Hong-Kong based Evergreen Land LTD. The transaction includes assets and IP and the exclusive right to commercialize the...